Quick View: AstraZeneca Strengthens Radiopharmaceuticals Portfolio With Fusion Acquisition
Pharmaceuticals / United Kingdom / Thu 21 Mar, 2024
The Latest: On March 19 2024, AstraZeneca announced it has agreed to acquire Fusion Pharmaceuticals, a company focused on the development of radioconjugates for cancer, in a deal worth up to USD2.4bn. Radioconjugates are an emerging class of targeted cancer treatment that work by combining antibodies with small molecules or peptides that are then